Alswat Khalid, Aljumah Abdulrahman A, Sanai Faisal M, Abaalkhail Faisal, Alghamdi Mohamed, Al Hamoudi Waleed K, Al Khathlan Abdullah, Al Quraishi Huda, Al Rifai Ahmed, Al Zaabi Mohamed, Babatin Mohamed A, Estes Chris, Hashim Almoutaz, Razavi Homie
Liver Disease Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Hepatology Division, Department of Hepatobiliary Sciences and Organ Transplant Center, King Abdulaziz Medical City; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.
Saudi J Gastroenterol. 2018 Jul-Aug;24(4):211-219. doi: 10.4103/sjg.SJG_122_18.
BACKGROUND/AIM: Due to epidemic levels of obesity and type 2 diabetes mellitus (DM), nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) will be driving factors in liver disease burden in the coming years in Saudi Arabia and United Arab Emirates (UAE). MATERIALS AND METHODS: Models were used to estimate NAFLD and NASH disease progression, primarily based on changes in adult prevalence rates of adult obesity and DM. The published estimates and expert interviews were used to build and validate the model projections. RESULTS: In both countries, the prevalence of NAFLD increased through 2030 parallel to projected increases in the prevalence of obesity and DM. By 2030, there were an estimated 12,534,000 NAFLD cases in Saudi Arabia and 372,000 cases in UAE. Increases in NASH cases were relatively greater than the NAFLD cases due to aging of the population and disease progression. Likewise, prevalent cases of compensated cirrhosis and advanced liver disease are projected to at least double by 2030, while annual incident liver deaths increase in both countries to 4800 deaths in Saudi Arabia and 140 deaths in UAE. CONCLUSIONS: Continued high rates of adult obesity and DM, in combination with aging populations, suggest that advanced liver disease and mortality attributable to NAFLD/NASH will increase across both countries. Reducing the growth of the NAFLD population, along with potential therapeutic options, will be needed to reduce liver disease burden.
背景/目的:由于肥胖症和2型糖尿病(DM)的流行程度,非酒精性脂肪性肝病(NAFLD)及其导致的非酒精性脂肪性肝炎(NASH)将在未来几年成为沙特阿拉伯和阿拉伯联合酋长国(阿联酋)肝脏疾病负担的驱动因素。 材料与方法:主要基于成人肥胖症和DM患病率的变化,使用模型来估计NAFLD和NASH疾病的进展情况。已发表的估计数据和专家访谈被用于构建和验证模型预测。 结果:在这两个国家,到2030年NAFLD的患病率随着肥胖症和DM患病率的预计增加而上升。到2030年,沙特阿拉伯估计有1253.4万例NAFLD病例,阿联酋有37.2万例。由于人口老龄化和疾病进展,NASH病例的增加相对大于NAFLD病例。同样,预计到2030年,代偿性肝硬化和晚期肝病的普遍病例至少会增加一倍,而两国每年的肝病死亡人数将分别增至沙特阿拉伯的4800例和阿联酋的140例。 结论:成人肥胖症和DM的持续高发病率,再加上人口老龄化,表明这两个国家归因于NAFLD/NASH的晚期肝病和死亡率将会增加。需要减少NAFLD人群的增长,并探索潜在的治疗选择,以减轻肝脏疾病负担。
Saudi J Gastroenterol. 2018
J Gastroenterol Hepatol. 2020-2-26
World J Gastroenterol. 2020-7-7
Swiss Med Wkly. 2019-12-17
World J Gastroenterol. 2017-12-21
Oman Med J. 2025-1-31
Cureus. 2025-4-10
Diabetol Metab Syndr. 2017-11-2
J Epidemiol Glob Health. 2017-12
Open Access Maced J Med Sci. 2017-10-14
N Engl J Med. 2017-7-6
Int J Health Sci (Qassim). 2016-7